Shorter treatment for lung tuberculosis with two existing medicines
Part of Infections, Lungs & breathing clinical trials.
This study tests a new combination of two existing medicines (pyrazinamide and hydroxychloroquine) to see if it works as well as the current standard treatment for TB. If it works, it could mean fewer pills or a shorter treatment for patients with drug-sensitive TB.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have tuberculosis (TB) in your lungs, confirmed by a lab test
- You are between 18 and 65 years old
- You have not had TB treatment before (or only for less than a month)
- If you have HIV, your CD4 count is at least 200 and you are on stable HIV medication
- You do not have TB that is resistant to the standard drugs
- You are not pregnant or breastfeeding, and you have no serious liver or kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a new, all-oral, shorter treatment regimen for tuberculosis that is resistant to rifampicin, a key antibiotic. It may offer a more convenient and effective option for patients with this difficult-to-treat infection.
This trial tests a shorter treatment course (instead of the standard 6 months) for people with low-risk active TB in the lungs. It aims to see if the shorter regimen works just as well and has fewer side effects.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.